v3.26.1
Collaboration Agreements - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 6 Months Ended 12 Months Ended 42 Months Ended
Jan. 27, 2023
Dec. 13, 2022
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Dec. 31, 2023
Jun. 30, 2026
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Deferred revenue, net of current portion     $ 13,904   $ 13,904   $ 7,798   $ 13,904
Shares issued under equity agreement   10,683,761              
Investment, Type [Extensible Enumeration]   G S K Equity Investment [Member]              
Purchase price per share   $ 4.68              
Collaboration revenue recognized     2,272 $ 8,699 40,518 $ 17,874      
Collaboration and license agreement, deferred revenue current     8,703   8,703   44,440   8,703
GSK Collaboration Agreement [Member]                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Upfront payment under collaboration agreement $ 120,000 $ 120,000              
Collaboration Agreement in Premium   $ 15,400              
Deferred revenue, net of current portion     13,900   13,900   7,800   13,900
Aggregate initiation payment         32,000        
Milestone payment             10,000 $ 20,000  
Collaboration revenue recognized     2,300 $ 8,700 40,500 $ 17,900     186,500
Contract with Customer, Liability, Total     22,600   22,600   52,200   22,600
Collaboration and license agreement, deferred revenue current     $ 8,700   $ 8,700   $ 44,400   $ 8,700